Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

被引:112
作者
Serfaty, L
Chazouilleres, O
Pawlotsky, JM
Andreani, T
Pellet, C
Poupon, R
机构
[1] HOP ST ANTOINE,SERV HEPATOL,F-75571 PARIS,FRANCE
[2] HOP HENRI MONDOR,SERV BACTERIOL VIROL,F-94010 CRETEIL,FRANCE
关键词
D O I
10.1053/gast.1996.v110.pm8536870
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Chronic hepatitis C virus carriers may have repeatedly normal aminotransferase activity despite detectable viremia and histological hepatitis. The aim of this study was to determine the effect of interferon in this population, Methods: Three million units of interferon alfa was administered 3 times weekly for 6 months in 10 patients with chronic hepatitis C virus infection, repeatedly normal alanine aminotransferase activity, and chronic hepatitis on liver biopsy, Serum hepatitis C virus RNA was detected by polymerase chain reaction and quantified by branched DNA before, at the end, and 1 year after treatment. A liver biopsy was performed 1 year after treatment withdrawal, Results: At treatment withdrawal, hepatitis C virus RNA levels had significantly decreased, but RNA was still detectable by polymerase chain reaction in 8 of 10 patients, During the 1-year follow-up period, 6 of 9 patients had elevated aminotransferase activity on at least one occasion, One year after treatment withdrawal, RNA levels had returned to pretreatment values and no significant histological improvement was observed in the 7 patients who underwent liver biopsy. Conclusions: In patients with chronic hepatitis C and repeatedly normal aminotransferase activity, standard interferon therapy does not lead to sustained virological or histological responses despite a transient effect on hepatitis C virus replication.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 29 条
[1]   HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV [J].
ALBERTI, A ;
MORSICA, G ;
CHEMELLO, L ;
CAVALLETTO, D ;
NOVENTA, F ;
PONTISSO, P ;
RUOL, A .
LANCET, 1992, 340 (8821) :697-698
[2]   THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS [J].
BARON, S ;
TYRING, SK ;
FLEISCHMANN, WR ;
COPPENHAVER, DH ;
NIESEL, DW ;
KLIMPEL, GR ;
STANTON, GJ ;
HUGHES, TK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (10) :1375-1383
[3]  
BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1002/hep.1840210306
[4]   PILOT-STUDY OF COMBINATION THERAPY WITH RIBAVIRIN PLUS INTERFERON-ALFA FOR INTERFERON ALFA-RESISTANT CHRONIC HEPATITIS-C [J].
BRILLANTI, S ;
GARSON, J ;
FOLI, M ;
WHITBY, K ;
DEAVILLE, R ;
MASCI, C ;
MIGLIOLI, M ;
BARBARA, L .
GASTROENTEROLOGY, 1994, 107 (03) :812-817
[5]   COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS [J].
CAUSSE, X ;
GODINOT, H ;
CHEVALLIER, M ;
CHOSSEGROS, P ;
ZOULIM, F ;
OUZAN, D ;
HEYRAUD, JP ;
FONTANGES, T ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
TREPO, C .
GASTROENTEROLOGY, 1991, 101 (02) :497-502
[6]  
DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A
[7]   HIGH-RATE OF INFECTIVITY AND LIVER-DISEASE IN BLOOD-DONORS WITH ANTIBODIES TO HEPATITIS-C VIRUS [J].
ESTEBAN, JI ;
LOPEZTALAVERA, JC ;
GENESCA, J ;
MADOZ, P ;
VILADOMIU, L ;
MUNIZ, E ;
MARTINVEGA, C ;
ROSELL, M ;
ALLENDE, H ;
VIDAL, X ;
GONZALEZ, A ;
HERNANDEZ, JM ;
ESTEBAN, R ;
GUARDIA, J .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :443-449
[8]  
ESTEBAN JI, 1989, LANCET, V2, P294
[9]  
GARCIABUEY L, 1991, HEPATOLOGY, V14, pA204
[10]   LONG-TERM FOLLOW-UP OF POSTTRANSFUSION AND SPORADIC CHRONIC HEPATITIS NON-A, NON-B AND FREQUENCY OF CIRCULATING ANTIBODIES TO HEPATITIS-C VIRUS (HCV) [J].
HOPF, U ;
MOLLER, B ;
KUTHER, D ;
STEMEROWICZ, R ;
LOBECK, H ;
LUDTKEHANDJERY, A ;
WALTER, E ;
BLUM, HE ;
ROGGENDORF, M ;
DEINHARDT, F .
JOURNAL OF HEPATOLOGY, 1990, 10 (01) :69-76